RxDoctor Payments DataLook up a doctor →

Booth Durham, MD

Dermatology · Sewell, NJNPI 1740392075

Payments from drug & device makers

$33,707in general payments, 2019–2025

Across 1,311 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$5K
  • Novartis$4K
  • Pfizer$3K
  • AbbVie$3K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$2K
  • Lilly USA, LLC$2K
  • plus $15K from 47 others

What the payments were for

  • Consulting fees$2,8008%
  • Speaking & faculty fees$5,78217%
  • Food & beverage$24,54573%
  • Education$5802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,707 in reported general payments places this provider in the 85th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,314,270
Medicare patients
747
Services billed
11,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab21$152,994
Humira(Cf) PenAdalimumab14$95,361
Dupixent PenDupilumab22$80,570
SiliqBrodalumab14$70,420
Dupixent SyringeDupilumab13$47,587
OpzeluraRuxolitinib Phosphate20$37,318
Ketoconazole109$3,172
Metronidazole33$3,086
Fluorouracil42$2,764
Clobetasol Propionate43$2,564
Triamcinolone Acetonide185$2,040
Desoximetasone14$1,853
Tacrolimus17$1,768
Doxycycline Monohydrate50$1,676
Betamethasone Dipropionate37$1,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq$1,828$70,42014 claims
Incyte CorporationOpzelura$1,146$37,31820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 394 dermatology providers in New Jersey.

Other dermatology in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →